

Global Colorectal Cancer Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

<https://marketpublishers.com/r/G04175922F8EN.html>

Date: November 2017

Pages: 211

Price: US\$ 4,400.00 (Single User License)

ID: G04175922F8EN

Abstracts

Colorectal cancer is also known as bowel cancer. It refers to the abnormal growth of the cells in colon and rectum due to cancer. Colorectal cancer starts either in the colon and rectum. Cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain.

Global colorectal cancer market is driven by some of the major factors such as increasing prevalence of colorectal cancer, technological advancements in the cancer therapy, aging population, and raise in consumer awareness about colorectal cancers. However, high costs of screening tests and drugs, lack of knowledge are some of the restraints that are hampering the growth of the global colorectal cancer drugs market.

The global colorectal cancer drugs market is segmented by therapy, drug class, distribution channel, and regions.

On the basis of therapy, global colorectal cancer drugs market is segmented as

Adjuvant chemotherapy

Palliative chemotherapy

Immuno therapy

Neo adjuvant chemotherapy

On the basis of drug class, global colorectal cancer drugs market is segmented as

Capecitabine (Xeloda)

Irinotecan (Camptosar)

Fluorouracil (5-FU, Adrucil)

Trifluridine/tipiracil (TAS-102, Lonsurf)

Oxaliplatin (Eloxatin)

Others

Some common treatment regimens using these drugs include:

5-FU

Capecitabine, an oral form of 5-FU

5-FU with leucovorin (Wellcovorin), a vitamin that improves the effectiveness of 5-FU

FOLFIRI: 5-FU with leucovorin and irinotecan

FOLFOX: 5-FU with leucovorin and oxaliplatin

Irinotecan alone

XELOX/CAPEOX: Capecitabine with oxaliplatin

XELIRI/CAPIRI: Capecitabine with irinotecan

On the basis of distribution channel, the global colorectal cancer drugs market is segmented as

Retail Pharmacies

Hospital Pharmacies

Others

Colorectal cancer is the third most common cancer in the world. Huge government initiatives taken by the nations are booming up the growth of the colorectal cancer drugs treatment market globally. Biologics such as Zaltrap (Ziv-Aflibercept), Erbitux (Cetuximab), Avastin (Bevacizumab) are used rapidly for the treatment of colorectal cancer that are used as a targeted therapy and they act only on the malignant cells. Market players in the colorectal cancer drugs market are forming strategic alliances and partnerships to increase their market share.

Geographically, global colorectal cancer treatment market is segmented into five key regions such as Latin America, North America, Asia-Pacific, Europe and The Middle East and Africa. North America is expected to grow at a significant rate in the colorectal cancer drugs market owing to the growing incidence of colorectal cancer and widespread awareness about early diagnosis and treatment of colorectal cancer. The Asia Pacific region is expected to have rapid growth in the market during the forecast period owing to huge population densities and high incidence of colorectal cancer in countries such as India and China.

Some of the players in the colorectal cancer drugs market are Amgen Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), and Sanofi (France) to name a few.

In Aug 2016, Sanofi's Zaltrap received U.S. FDA approval to use with FOLFIRI to treat adult patients having colorectal cancer

In May 23, 2014, the U.S. Food and Drug Administration (FDA) approved for Amgen's Vectibix (panitumumab) for use in combination with FOLFOX, to treat metastatic colorectal cancer

In Sept. 16, 2013, Genentech received U.S. FDA approval for the first generic version of Xeloda, to treat cancer of the colorectal cancer

In Sept 2012, The USFDA approved Stivarga (regorafenib) (Bayer) tablets to treat patients with collateral cancer

REPORT OUTLINE:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023

The report covers in-detail insights about the competitor's overview, key findings and their key strategies

The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup's details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL COLORECTAL CANCER DRUGS MARKET INTRODUCTION

2.1. Global Colorectal Cancer Drugs Market– Taxonomy

2.2. Global Colorectal Cancer Drugs Market–Definitions

2.2.1. Drug Type

2.2.2. Therapy

3. GLOBAL COLORECTAL CANCER DRUGS MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Colorectal Cancer Drugs Market Dynamics – Factors Impact Analysis

3.6. Global Colorectal Cancer Drugs Market– Recent Market Introductions

4. GLOBAL COLORECTAL CANCER DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL COLORECTAL CANCER DRUGS MARKET FORECAST, BY THERAPY, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Adjuvant Chemotherapy

5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Palliative Chemotherapy

5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Immuno Therapy

- 5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.3.3. Market Opportunity Analysis
- 5.4. Neo Adjuvant Chemotherapy
 - 5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 5.4.3. Market Opportunity Analysis

6. GLOBAL COLORECTAL CANCER DRUGS MARKET FORECAST, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

- 6.1. Capecitabine
 - 6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.1.3. Market Opportunity Analysis
- 6.2. Irinotecan
 - 6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.2.3. Market Opportunity Analysis
- 6.3. Fluorouracil
 - 6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.3.3. Market Opportunity Analysis
- 6.4. Trifluridine/tipiracil
 - 6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.4.3. Market Opportunity Analysis
- 6.5. Oxaliplatin
 - 6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.5.3. Market Opportunity Analysis
- 6.6. Others
 - 6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.6.3. Market Opportunity Analysis

7. GLOBAL COLORECTAL CANCER DRUGS MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospital Pharmacies

- 7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.1.3. Market Opportunity Analysis

7.2. Retail Pharmacies

- 7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.2.3. Market Opportunity Analysis

7.3. Online Pharmacies

- 7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.3.3. Market Opportunity Analysis

8. GLOBAL COLORECTAL CANCER DRUGS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America

- 8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.1.3. Market Opportunity Analysis

8.2. Europe

- 8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

- 8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.3.3. Market Opportunity Analysis

8.4. Latin America

- 8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

- 8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.5.3. Market Opportunity Analysis

8.6. Global Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Region, 2017 – 2023

9. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.1.1. Adjuvant Chemotherapy

9.1.1.2. Palliative Chemotherapy

9.1.1.3. Immuno Therapy

9.1.1.4. Neo Adjuvant Chemotherapy

9.1.2. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.2.1. Capecitabine

9.1.2.2. Irinotecan

9.1.2.3. Fluorouracil

9.1.2.4. Trifluridine/tipiracil

9.1.2.5. Oxaliplatin

9.1.2.6. Others

9.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.3.1. Retail Pharmacies

9.1.3.2. Hospital Pharmacies

9.1.3.3. Online Pharmacies

9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.1.4.1. U.S.

9.1.4.2. Canada

9.1.5. North America Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Country, 2017 – 2023

9.1.6. North America Colorectal Cancer Drugs Market Dynamics – Trends

10. EUROPE COLORECTAL CANCER DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.1.1. Adjuvant Chemotherapy

10.1.1.2. Palliative Chemotherapy

10.1.1.3. Immuno Therapy

10.1.1.4. Neo Adjuvant Chemotherapy

10.1.2. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.2.1. Capecitabine

10.1.2.2. Irinotecan

10.1.2.3. Fluorouracil

10.1.2.4. Trifluridine/tipiracil

10.1.2.5. Oxaliplatin

10.1.2.6. Others

10.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.3.1. Retail Pharmacies

10.1.3.2. Hospital Pharmacies

10.1.3.3. Online Pharmacies

10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.4.1. Germany

10.1.4.2. UK

10.1.4.3. France

10.1.4.4. Spain

10.1.4.5. Italy

10.1.4.6. Russia

10.1.4.7. Poland

10.1.4.8. Rest of Europe

10.1.5. Europe Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Country, 2017 – 2023

10.1.6. Europe Colorectal Cancer Drugs Market Dynamics – Trends

11. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.1.1. Adjuvant Chemotherapy

11.1.1.2. Palliative Chemotherapy

11.1.1.3. Immuno Therapy

11.1.1.4. Neo Adjuvant Chemotherapy

11.1.2. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.2.1. Capecitabine

11.1.2.2. Irinotecan

11.1.2.3. Fluorouracil

11.1.2.4. Trifluridine/tipiracil

11.1.2.5. Oxaliplatin

11.1.2.6. Others

11.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.3.1. Retail Pharmacies

11.1.3.2. Hospital Pharmacies

11.1.3.3. Online Pharmacies

11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

11.1.4.1. Japan

11.1.4.2. China

11.1.4.3. India

11.1.4.4. ASEAN

11.1.4.5. Australia & New Zealand

11.1.4.6. Rest of Asia-Pacific

11.1.5. Asia-Pacific Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Country, 2017 – 2023

11.1.6. Asia-Pacific Colorectal Cancer Drugs Market Dynamics – Trends

12. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.1.1. Adjuvant Chemotherapy

12.1.1.2. Palliative Chemotherapy

12.1.1.3. Immuno Therapy

12.1.1.4. Neo Adjuvant Chemotherapy

12.1.2. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.2.1. Capecitabine

12.1.2.2. Irinotecan

12.1.2.3. Fluorouracil

12.1.2.4. Trifluridine/tipiracil

12.1.2.5. Oxaliplatin

12.1.2.6. Others

12.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.3.1. Retail Pharmacies

12.1.3.2. Hospital Pharmacies

12.1.3.3. Online Pharmacies

12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.4.1. Brazil

12.1.4.2. Mexico

12.1.4.3. Argentina

12.1.4.4. Venezuela

12.1.4.5. Rest of Latin America

12.1.5. Latin America Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Country, 2017 – 2023

12.1.6. Latin America Colorectal Cancer Drugs Market Dynamics – Trends

13. MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.1.1. Adjuvant Chemotherapy

13.1.1.2. Palliative Chemotherapy

13.1.1.3. Immuno Therapy

13.1.1.4. Neo Adjuvant Chemotherapy

13.1.2. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.2.1. Capecitabine

13.1.2.2. Irinotecan

13.1.2.3. Fluorouracil

13.1.2.4. Trifluridine/tipiracil

13.1.2.5. Oxaliplatin

13.1.2.6. Others

13.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.3.1. Retail Pharmacies

13.1.3.2. Hospital Pharmacies

13.1.3.3. Online Pharmacies

13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.4.1. Gulf Cooperation Council (GCC) Countries

13.1.4.2. Israel

13.1.4.3. South Africa

13.1.4.4. Rest of MEA

13.1.5. MEA Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Country, 2017 – 2023

13.1.6. MEA Colorectal Cancer Drugs Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. Amgen Inc. (U.S)

14.2.2. Bristol-Myers Squibb Company (U.S.)

14.2.3. F. Hoffmann-La Roche Ltd. (Switzerland)

14.2.4. Bayer AG (Germany)

14.2.5. Merck & Co., Inc. (U.S.)

14.2.6. Sanofi (France)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: Global Colorectal Cancer Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Product link: <https://marketpublishers.com/r/G04175922F8EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G04175922F8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

